topical BRAF inhibitor (gel) for EGFRi rash
Ph. I in mCRC with EGFRi-related rash
paradoxical activ. of MAPK to counter EGFRi
Cancer Discovery, May 25, 2021
Lutris-Parma, Tel Aviv, IL / MSKCC, NY
LUT014
The Lutris-Parma topical BRAF inhibitor, LUT014, is intended to treat rash caused by EGFR inhibitors. Rash is a significant and common side effect of EGFR inhibitor treatment leading to worse…